Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Pharmacokinetics of Intravenous CR845 in Hemodialysis Patients, and Its Safety and Efficacy in Hemodialysis Patients With Uremic Pruritus

NCT02229929 is registered in ClinicalTrials.gov with Cara Therapeutics, Inc. as lead sponsor.

NCT NCT02229929
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02229929 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Pharmacokinetics of Intravenous CR845 in Hemodialysis Patients, and Its Safety and Efficacy in Hemodialysis Patients With Uremic Pruritus
Lead sponsor
Cara Therapeutics, Inc.
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2014
Completion date
July 31, 2015
Enrollment
89 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

pruritus, uremic pruritus